Showing results (171-180 of 193) with videos related to

Sort By:
Pageof 20
NPJ Vaccines|February 7, 2020
Immunization with full-length <i>Plasmodium falciparum</i> merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trialAntje Blank, Kristin Fürle, Anja Jäschke, et al.
European Journal of Clinical Pharmacology|December 25, 2004
Pharmacokinetic interaction of chloroquine and methylene blue combination against malariaJens Rengelshausen, Jürgen Burhenne, Margit Fröhlich, et al.
European Journal of Clinical Pharmacology|August 8, 2019
Dose evaluation of intravenous metamizole (dipyrone) in infants and children: a prospective population pharmacokinetic studyVictoria C Ziesenitz, Frédérique Rodieux, Andrew Atkinson, et al.
Journal of Clinical Pharmacology|March 18, 2024
Pharmacokinetics-Based Pediatric Dose Evaluation and Optimization Using Saliva - A Case StudyMarion Anliker-Ort, Frédérique Rodieux, Victoria C Ziesenitz, et al.
Clinical Pharmacology in Drug Development|July 16, 2021
Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy AdultsFelicitas Stoll, Antje Blank, Gerd Mikus, et al.
Infection|April 25, 2025
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational studyFranz Weber, Christina Scharf, Linda B S Aulin, et al.
Tropical Medicine & International Health : TM & IH|April 9, 2010
Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina FasoMamadou Bountogo, Augustin Zoungrana, Boubacar Coulibaly, et al.
Cardiovascular Drugs and Therapy|December 19, 2023
Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and RosuvastatinEvelyn Krohmer, Brit Silja Rohr, Felicitas Stoll, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 12, 2023
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary SyndromesMichael Böttcher, Hans-Dirk Düngen, Vasile Corcea, et al.
European Journal of Clinical Pharmacology|January 9, 2017
Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trialsKerstin Breithaupt-Groegler, Christoph Coch, Martin Coenen, et al.
Pageof 20